MONTCLAIR, NJ--(Marketwired - Feb 26, 2014) - MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today that it has been invited to present at the upcoming 26th Annual ROTH Conference. The conference will be held on March 9-12, 2014 at The Ritz-Carlton Laguna Niguel in Dana Point, California. MetaStat will be presenting on Wednesday, March 12, 2014 at 12:30 pm (PT).
MetaStat's Chief Executive Officer, Oscar Bronsther, M.D., will present an overview of the company and provide an update on MetaStat's novel diagnostic and therapeutic approaches to systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body.
Dr. Bronsther stated, "With our recently completed MetaSite Breast™ trial and the opening of our drug discovery laboratory, we believe we are well positioned to deliver our breast cancer diagnostics to the market in 2015 and validate our novel drug targets." Dr. Bronsther continued, "We believe this is a great opportunity to create visibility and investor awareness for our company and we are excited to have the opportunity to present at the ROTH Conference."
To arrange a one-on-one meeting with management, please contact Robert Haag at firstname.lastname@example.org or 1-866-976-4784.
About the 26th Annual ROTH Conference
The annual ROTH Conference is one of the largest of its kind in the U.S., bringing together executives from hundreds of growth companies. This event is designed to provide investors with a unique opportunity to gain insight into emerging growth companies across a variety of sectors, including Cleantech, Consumer & Retail, Energy & Industrial, Enterprise Software, Healthcare, Resources, Semiconductors & Electronics, Services and Technology & Media. The conference will feature company presentations, Q&A sessions, expert panels and thousands of management one-on-one and small group meetings.
About MetaStat, Inc.
MetaStat is a life sciences company that develops and commercializes diagnostic products and novel therapeutics for the early and reliable prediction and treatment of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The Company's function-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ product lines are designed to accurately stratify patients based on their individual risk of metastasis and to allow clinicians to better "customize" cancer treatment decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. Additionally, the MenaBloc™ therapeutic program aims to build upon mena biology and alternative splicing events as a driver of disease progression to exploit novel targets that provide precision medicines in oncology.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.